Ann: NOX announces Positive Data from CEP-1 Study of Veyonda, page-2

Back in 2011
"There were no treatment-related deaths. There was only one treatment-related hospitalization and 2 grade 4 toxicities. In the cisplatin arm, there were 3 partial responses, 9 patients (56%) achieved stable disease, 4 (25%) progressed, and the overall best response rate was 19%. In the paclitaxel arm, there was one complete response and 2 partial responses, 8 patients (53%) achieved stable disease, 4 patients (27%) progressed, and the overall best response rate was 20%."
https://www.ncbi.nlm.nih.gov/pubmed/21412168?dopt=Abstract

Now - 13-Nov-2018
A phase 1 study of NOX66 in combination with carboplatin in patients with end stage solid tumours
Poster at COSA Annual Meeting Perth November 2018

"Of the 16 evaluable patients receiving one dose of Nox66 best radiological overall responses by RECIST criteria was stablistion of disease in 45% of patients by end of study cycle 6. One patient 800mg dosage with metastatic breast cancer had evidence of partial overall response" "https://www.noxopharm.com/site/PDF/...carboplatininpatientswithendstagesolidtumours

"To date a significant number of clinical trials involving isoflavonoids have been undertaken. None of these trials have demonstrated consistent efficacy. For example, Idronoxil has held an IND from the US FDA since about 2000 in both oral and intravenous dosage formulations and in that form has undergone over 12 Phase 1 , Phase 2 and Phase 3 clinical studies in over 300 patients with late-stage cancers. Instances of clinical response (complete response, partial response, stable disease) have been observed, but neither dosage formulation has delivered a consistent, clinically meaningful anti-cancer effect."
https://patentscope.wipo.int/search...ing=FP:(noxopharm)&recNum=7&maxRec=12

And today nothing has changed.